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OBJECTIVES: Constipation is considered an inconvenient problem, however data
on the real burden is lacking. The objective of the current analysis was to assess the
clinical and economic burden of chronic constipation in Belgium.METHODS: From
the IMS Hospital Disease Database (year 2007), which includes data on full hospi-
talizations and day clinic for 34.3% of Belgian hospital beds, stays of patients with
constipation were selected based on the ICD-9-CM code (564.0) with constipation as
a primary diagnosis. The database allows to estimate length of stay (LOS), in-
hospital mortality, performed interventions, ATC classified medication usage, and
cost of hospitalisation. Using the 34% coverage, a national projection was made for
the number of hospital stays and burden of disease. 2007 costs were extrapolated to
2010 using progression in costs from 2001 to 2007. ATC codes for osmotic/contact
laxatives, softeners, bulking agents, enemas and peripheral opioid receptor antag-
onists were used. Occurrence of relevant co-morbidities was analyzed using appli-
cable ICD-9-CM codes. RESULTS: There were 6338 hospital day clinic stays and full
hospitalizations (LOS 5.44 days). About 42% of the patients were admitted via the
ER. Most occurring co-morbidities were hemorrhoids (174), fecal impaction (74) and
intestinal obstruction (53). Mortality rate was 0.46% meaning 29 deaths in hospi-
talizations for constipation. Especially in hospitalized patients, usage of enemas
was pronounced (34.17%). Osmotically acting laxatives are the most used agents
(39.58%). The average costs per patient was €1883, consisting of medication costs,
procedural costs and stay costs of €112, €675 and €1097, respectively. Extrapolated
to Belgium the total hospitalization cost for constipation was approximately €11.9
million. Hospital stay is more frequent in the elderly particularly in elderly females.
CONCLUSIONS: Constipation is an underestimated disease condition reflected by
hospital related costs of about €11.9 million and approximately 29 death cases in
Belgium in 2007.
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OBJECTIVES: The aim of this study was to assess disease stage dependent resource
use and costs in chronic genotype 1 hepatitis C (CHC) patients in Belgium.
METHODS: The medical records of 157 CHC patients were reviewed to identify
medical costs over a follow up period of 3 years. Six disease stages were defined
based on histology/clinical data: mild disease (F0-F2), moderate disease (F3) or
compensated cirrhosis without varices (F4), compensated cirrhosis with varices
(F4), decompensated cirrhosis, hepatocellular carcinoma (HCC) and liver trans-
plantation (LT). Data collected were baseline demographic characteristics, HCV-
related data and detailed resource use (hospitalizations, day-clinic visits, surgery/
interventions, physician visits, diagnostic tests and drug use). Resource use items
were multiplied with unit costs (2010) to calculate costs. The public health care
payer’s (HCP) perspective was taken including the health insurance and patient
co-payment. RESULTS: Intravenous/intranasal drug use was reported in circa 20%
of patients, 63% had co-morbidities at study start. Nineteen patients (12%) died
during the study period, whereof 79% attributable to HCV. Average number of
hospitalizations during the study period ranged between 0.4 (mild disease) and 5.3
(HCC). Cost of care during the study period ranged from €18,993 for mild disease (in
81% due to HCV drug treatment) to €35,987 for patients with HCC (in 83% due to
hospitalization, 11% due to medication and in 6% due to ambulatory care) and
€65,120 for patients who underwent a liver transplant (79% hospitalization, 18%
medication, 3% ambulatory care). Cost of diagnosis of the disease stage ranged
between €790 (F3-F4 without varices) and €4142 (decompensated cirrhosis).
CONCLUSIONS: Antiviral treatment is the most important cost driver in mild &
moderate disease, but once complications of CHC occur, the associated costs far
exceed this cost of antiviral therapy.
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OBJECTIVES: Hepatitis C (HCV) is a disease which in the long run can lead to
cirrhosis and liver cancer, resulting in liver transplantation or death if not treated
properly. So far, there is a paucity of literature on health care costs and quality of
life (QoL) of HCV management. This study aims to illustrate the health care costs
and QoL associated with HCV in The Netherlands. METHODS: This study followed
a cross-sectional design for QoL and indirect costs, and a retrospective design for
direct costs (these were mapped retrospectively until 3 years ago or diagnosis of
HCV if earlier). Patients with HCV genotype 1 at Erasmus MC were invited to par-
ticipate between November 2010 and April 2011. Patients were asked to complete
the EQ-5D, Short form 36 (SF-36), Liver disease symptom index (LDSI) and Short
form health and labour questionnaire (SF-HLQ). Resource use data were collected
from the hospital information system. Utilities were determined using the UK tariff
for EQ-5D The Mann-Whitney U-test was used for comparisons between treated
and non-treated patients for the disease categories, mild and moderate disease and
cirrhosis. RESULTS: Thirty-seven patients had either completed or discontinued
treatment during the observation period, 10 had achieved sustained viral response
(SVR). Mean direct costs were higher for treated patients, during all 3 years of
observation; 3286 versus 5361, 1336 versus 9440, 2538 versus 10.507, (p0.01). Com-
pared to non-responders successfully treated patients had lower follow-up costs 1
year after treatment, 1172 versus 1426, and a higher mean utility, 0.84 versus 0.70,
neither result was statistically significant at p0.4 and p0.2. There were no sig-
nificant differences in indirect costs. CONCLUSIONS: This study provides basic
information about the costs and utility of hepatitis C treatment. Such information
is valuable when considering cost-effectiveness of new treatments for this disease.
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OBJECTIVES: As a result of successful treatments for chronic hepatic diseases
(CHDs), patients’ life expectancy, but also the diseases prevalence and costs are
increasing. However, societal costs for CHDs remain little known. We assessed
treatment and productivity costs of patients with CHDs in Italy. METHODS: a nat-
uralistic multicentre Cost-of-Illness study was conducted. Adult patients (age18
years) diagnosed with CHDs, consequently accessing at gastroenterology unit of 2
hospitals, were enrolled. Direct and indirect costs were assessed from the societal
perspective, reported as mean €/patient-month (treatment cost) and mean days/
patient-month of work/school/usual activities lost (productivity loss). The patients
were sub-grouped according to their main condition at the enrollment: hepatitis B,
hepatitis C, cirrhosis, liver transplantation, hepatic carcinoma. RESULTS: We en-
rolled 1,088 valid patients, 62.0% male (N675), aged 19-90 (median60) years:
31.5% (N342) has hepatitis C, 20.3% (N220) cirrhosis, 19.8% (N216) hepatitis B,
11.9% (N129) had liver transplantation, 7.5%(N82) hepatic carcinoma, 9.0%
(N99) had other hepatic diseases. Overall, their treatment cost was 278.26 €/pa-
tient-month: 96% for conventional drug treatment, 4% for unconventional treat-
ment (homeopathy, preparation of herbs, specific diet, multi-vitamin products).
Patients who received liver transplantation were the most expensive (1041.31€/
patient-month), followed by hepatitis B (249 €/month), hepatitis C (167 €/month).
Productivity loss corresponded to 4.9 days/patient-month, mainly by transplanted
patients (8.6 days/patient-month) and those with cirrhosis (8 days/patient-month).
CONCLUSIONS: CHDs sensitively contribute to the high cost and require appropri-
ate health technology valuations to guide stakeholders to find optimal diagnostic
and treatment strategies.
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OBJECTIVES: There is no published study about the direct costs linked to the pro-
cedure of the EC in Brazil. Our aim was to determine a base price of a single
procedure of EC. METHODS: Based on a micro cost approach, we first determined
the individual items that compose an EC procedure. Then we conducted a market
price search for each of them in order to compose the final total cost. For the
permanent equipment needed we considered an amortization time of 24 months
and a 1% monthly interest percent rate. RESULTS: An EC procedure requires an
initial investment in one computer and in one receiver, which is attached to the
patient to capture the capsule’s signal, known as “belt”. Included in the analysis
there are also the cost of the capsule per si, some medicines, the physician’s and
the room fee. The initial investment is US$19,411. Each capsule cost US$647 (single
use). A medical fee of US$380 was set, that include the administration of the cap-
sule, the supervision of the patient during the length of the procedure and the
interpretation of the exam. Considering a service that performs three exams a
month, a cost of US$1645 would be necessary to cover the expenses with material,
personnel (doctors included) and to pay the amortization costs, insurance and
interests for a 24 months period. CONCLUSIONS: In Brazil, the cost of EC procedure
may be set at US$1645 in order to cover the expenses of the services.
PGI18
TREATMENT OF CHRONIC HEPATITIS C PATIENTS WITH PEGINTERFERON
ALFA-2A OR PEGINTERFERON ALFA-2B: A COST-EFFECTIVENESS ANALYSIS FOR
THE PORTUGUESE NHS SETTING
Areias J1, Branco T2, Calinas F3, Carvalho A4, Macedo G5, Manata MJ6, Matos L7,
Rodrigues B8, Velosa J9, Pereira C10, Sanches M11, Rubio-Terrés C12
1Hospital Geral de Santo António, Porto, Portugal, 2Hospital Prof. Doutor Fernando da Fonseca,
EPE, Amadora, Portugal, 3Hospital de Santo António dos Capuchos, Lisbon, Portugal, 4Hospitais
da Universidade de Coimbra, Coimbra, Portugal, 5Hospital de São João, Porto, Portugal, 6Hospital
de Curry Cabral, Lisbon, Portugal, 7Hospital de Egas Moniz, Lisbon, Portugal, 8Hospital de Pulido
Valente, Lisbon, Portugal, 9Hospital de Santa Maria, Lisboa, Portugal, 10Roche Farmacêutica
Quimica, Lda., Amadora, Portugal, 11Roche Farmacêutica Química, Lda., Amadora, Portugal,
12HealthValue, Madrid, Spain
OBJECTIVES: Estimate long-term cost-effectiveness of treatment with peginter-
feron (pegINF) alfa-2a (180 mcg/week) in combination with ribavirin (RBV) (800 –
1200 mcg/day) versus pegINF alfa-2b (1.5 mcg/kg/week) in combination with RBV
(800- 1400 mg/day), in patients with Chronic Hepatitis C (CHC), from the Portuguese
National Health System (NHS) perspective. METHODS: To project disease progres-
sion, a seven-health state Markov model was built based on clinical stages of CHC.
Efficacy data was obtained from a published meta-analysis of 8 head-to-head ran-
domized trials that showed higher sustained virological response (SVR) in patients
receiving pegIFN alfa-2a compared to pegIFN alfa-2b. Effectiveness was measured
in terms of quality-adjusted life years. Transition probabilities and health state
utilities were obtained from published literature. Treatment duration was consid-
ered to be 48 and 24 weeks for genotypes 1/4 and 2/3, respectively. A Delphi panel
with Portuguese experts was conducted to evaluate direct medical resources asso-
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